Shares Outstanding Shares Outstanding n/a Close	7.94M
Shares Change (YoY) Shares Change (YoY) n/a Close	21.47%
Shares Change (QoQ) Shares Change (QoQ) n/a Close	0%
Owned by Institutions (%) Owned by Institutions (%) n/a Close	4.81%
Shares Floating Shares Floating n/a Close	6.17M
Failed to Deliver (FTD) Shares Failed to Deliver (FTD) Shares n/a Close	5,595
FTD / Avg. Volume FTD / Avg. Volume n/a Close	0.41%

Short Selling Information

The latest short interest is 536.94K, so 6.76% of the outstanding shares have been sold short.

Short Interest Short Interest n/a Close	536.94K
Short % of Shares Out Short % of Shares Out n/a Close	6.76%
Short % of Float Short % of Float n/a Close	7.48%
Short Ratio (days to cover) Short Ratio (days to cover) n/a Close	1

Valuation Ratios

The PE ratio is 1.04 and the forward PE ratio is -1.29. Brainstorm Cell Therapeutics's PEG ratio is 0.

PE Ratio PE Ratio n/a Close	1.04
Forward PE Forward PE n/a Close	-1.29
PS Ratio PS Ratio n/a Close	14.2
Forward PS Forward PS n/a Close	0
PB Ratio PB Ratio n/a Close	-1.55
P/FCF Ratio P/FCF Ratio n/a Close	-1.33
PEG Ratio PEG Ratio n/a Close	0

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Brainstorm Cell Therapeutics.

EV / Sales EV / Sales n/a Close	n/a
EV / EBITDA EV / EBITDA n/a Close	n/a
EV / EBIT EV / EBIT n/a Close	n/a
EV / FCF EV / FCF n/a Close	n/a

Financial Position

The company has a current ratio of 0.04, with a Debt / Equity ratio of -0.09.

Current Ratio Current Ratio n/a Close	0.04
Quick Ratio Quick Ratio n/a Close	0.04
Debt / Equity Debt / Equity n/a Close	-0.09
Debt / EBITDA Debt / EBITDA n/a Close	n/a
Debt / FCF Debt / FCF n/a Close	-0.08
Interest Coverage Interest Coverage n/a Close	0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity Return on Equity n/a Close	n/a
Return on Assets Return on Assets n/a Close	n/a
Return on Invested Capital Return on Invested Capital n/a Close	n/a
Revenue Per Employee Revenue Per Employee n/a Close	$31,444.44
Profits Per Employee Profits Per Employee n/a Close	$430,481.48
Employee Count Employee Count n/a Close	27
Asset Turnover Asset Turnover n/a Close	0.46
Inventory Turnover Inventory Turnover n/a Close	n/a

Taxes

Income Tax Income Tax n/a Close	n/a
Effective Tax Rate Effective Tax Rate n/a Close	0%

Stock Price Statistics

The stock price has increased by -79.67% in the last 52 weeks. The beta is 0.21, so Brainstorm Cell Therapeutics's price volatility has been higher than the market average.

Beta Beta n/a Close	0.21
52-Week Price Change 52-Week Price Change n/a Close	-79.67%
50-Day Moving Average 50-Day Moving Average n/a Close	1.13
200-Day Moving Average 200-Day Moving Average n/a Close	1.76
Relative Strength Index (RSI) Relative Strength Index (RSI) n/a Close	43.21
Average Volume (20 Days) Average Volume (20 Days) n/a Close	1,352,554

Income Statement

In the last 12 months, Brainstorm Cell Therapeutics had revenue of 849K and earned 11.62M in profits. Earnings per share was 2.19.

Revenue Revenue n/a Close	849K
Gross Profit Gross Profit n/a Close	849K
Operating Income Operating Income n/a Close	n/a
Net Income Net Income n/a Close	11.62M
EBITDA EBITDA n/a Close	n/a
EBIT EBIT n/a Close	n/a
Earnings Per Share (EPS) Earnings Per Share (EPS) n/a Close	2.19

Full Income Statement

Balance Sheet

The company has 187K in cash and 720K in debt, giving a net cash position of -533K.

Cash & Cash Equivalents Cash & Cash Equivalents n/a Close	187K
Total Debt Total Debt n/a Close	720K
Net Cash Net Cash n/a Close	-533K
Retained Earnings Retained Earnings n/a Close	-226.64M
Total Assets Total Assets n/a Close	1.83M
Working Capital Working Capital n/a Close	-8.59M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -9.09M and capital expenditures 0, giving a free cash flow of -9.09M.

Operating Cash Flow Operating Cash Flow n/a Close	-9.09M
Capital Expenditures Capital Expenditures n/a Close	n/a
Free Cash Flow Free Cash Flow n/a Close	-9.09M
FCF Per Share FCF Per Share n/a Close	-1.71

Full Cash Flow Statement

Margins

Gross margin is 100%, with operating and profit margins of 0% and 1369.02%.

Gross Margin Gross Margin n/a Close	100%
Operating Margin Operating Margin n/a Close	n/a
Pretax Margin Pretax Margin n/a Close	1369.02%
Profit Margin Profit Margin n/a Close	1369.02%
EBITDA Margin EBITDA Margin n/a Close	n/a
EBIT Margin EBIT Margin n/a Close	n/a
FCF Margin FCF Margin n/a Close	-1071.02%

Dividends & Yields

BCLI does not appear to pay any dividends at this time.

Dividend Per Share Dividend Per Share n/a Close	n/a
Dividend Yield Dividend Yield n/a Close	n/a
Dividend Growth (YoY) Dividend Growth (YoY) n/a Close	n/a
Payout Ratio Payout Ratio n/a Close	n/a
Earnings Yield Earnings Yield n/a Close	n/a
FCF Yield FCF Yield n/a Close	n/a

Dividend Details

Analyst Forecast

The average price target for BCLI is $30, which is 2627.3% higher than the current price. The consensus rating is "Buy".

Price Target Price Target n/a Close	$30
Price Target Difference Price Target Difference n/a Close	2627.3%
Analyst Consensus Analyst Consensus n/a Close	Buy
Analyst Count Analyst Count n/a Close	1

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value Lynch Fair Value n/a Close	n/a
Lynch Upside Lynch Upside n/a Close	n/a
Graham Number Graham Number n/a Close	n/a
Graham Upside Graham Upside n/a Close	n/a

Stock Splits

The last stock split was on Oct 1, 2024. It was a backward split with a ratio of 1:15.

Last Split Date Last Split Date n/a Close	Oct 1, 2024
Split Type Split Type n/a Close	backward
Split Ratio Split Ratio n/a Close	1:15

Scores

Altman Z-Score Altman Z-Score n/a Close	-199.36
Piotroski F-Score Piotroski F-Score n/a Close	1